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CD2 (known also as T11 [1], LFA-2 [2, 3], and the E rosette receptor [4]) is a
T lymphocyte surface glycoprotein of50-58 kD that appears early in thymocyte
ontogeny and is present on all mature T cells (5). mAbs to CD2 inhibit Th cell
antigen-stimulated proliferation and cytolytic T lymphocyte-mediated killing
(2-4, 6). CD2 mAbs inhibit an early step in T lymphocyte-mediated killing,
adhesion of the T lymphocyte to the target cell (7). The findings suggest that
CD2-mediated adhesion facilitates interaction of T lymphocytes with other cells.
Curiously, CD2 mAbs also inhibit rosetting of T lymphocytes with E (4, 8).
When human T lymphocytes are centrifuged with E of certain species and held
at 4'C, they are found to adhere to multiple E in delicate rosettes (9, 10).
Rosetting has long been used to purify T lymphocytes from peripheral blood,
and clinically to enumerate T lymphocyte subpopulations (11). Rosetting does
not involve the T cell antigen receptor. Sheep E rosette with essentially all human
T lymphocytes in peripheral blood and with thymocytes and activated T lym-
phocytes (9). A small percentage of human peripheral blood T lymphocytes will
form autologous rosettes with human E (12-14). Rosetting with autologous and
allogeneic E is equivalent. The subpopulation that forms autologous rosettes
mediates the autologous MLR (12, 15) and may thus be activated. Activated
human T lymphocytes, i.e ., thymocytes, T lymphoblasts, and T cell tumor lines,
vigorously rosette with human E (16). Rosetting of human T lymphocytes with
E from sheep, human, pig, and rabbit is inhibited by CD2 mAbs (8, 13, 17, 18),
and thus it has been inferred that CD2 is an E rosette receptor. We recently
purified CD2 to homogeneity and found that it inhibited sheep E rosetting and
was absorbed by sheep E (19) . This suggested to us that CD2 might bind to a
similar ligand on human E.
We have previously defined (3, 20) an antigen-independent pathway of T
lymphocyte adhesion to target cells that involves CD2 on the T lymphocyte and
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lymphocyte function-associated antigen 3 (LFA-3)' on the target cell . LFA-3 is
a glycoprotein of 55-70 kD that is broadly distributed on nonhematopoietic as
well as hematopoietic cells (2, 3) . mAbs to LFA-3 and CD2 inhibit a similar
spectrum of antigen-specific T cytolytic and Th cell responses (3) . Furthermore,
thymocyte rosetting with thymic epithelial cells is dependent on CD2 on the
thymocyte, and LFA-3 on the thymic epithelial cell (21) . These findings led us
to question whether autologous E rosetting was mediated by a CD2/LFA-3
interaction similar to that which is so important in physiologic T cell responses .
We have confirmed this hypothesis, and have used autologous E rosetting as a
model system to examine molecular interactions between CD2 and LFA-3 . We
demonstrate that purified CD2 binds to LFA-3 on E . Furthermore, purifiedCD2
can mediate cell-cell adhesion (aggregation) of E by binding to LFA-3 .
Materials and Methods
Cells.
￿
Fresh PBL or thymocytes were separated on lymphocyte separation medium
(Ficoll and diatrizoate salts, density 1 .077-1 .080 g/ml at 20°C) (Bionetics, Kensington,
MD). T lymphoblasts were obtained by stimulating PBL with 1 Ag/ml PHA (Sigma
Chemical Co ., St . Louis, MO) in RPMI 1640/10% FBS for 5 d, and they were washed in
RPMI 1640/10% FBS three times before use . Identical rosetting results were obtained
with PHA-PBL that had been washed free of PHA and cultured 1 d before use . The
Jurkat T lymphoma cell line was maintained in RPMI 1640 with 10% FBS . Where
indicated, lymphocytes (5 X 106/ml) in RPMI 1640/5% FBS were pretreated with 0.1%
bromelain or 0.2 U/ml neuraminidase (Calbiochem-Behring Corp ., La Jolla, CA) for 1 h
at 37°C . Cells were washed three times in RPMI 1640/10% FBS before addition to the
rosetting assay .
Monoclonal Antibodies.
￿
mAbs were TS2/18 (CD2), TS2/9 (LFA-3), TS1/22 (LFA-1)
(2), control P3X63 (myeloma IgGI), E3 (human glycophorin) (22), D44 (complement
receptor type 1 [CR11) (23), and IAIO (decay-accelerating factor [DAF]) (24) . A goat
anti-human glycophorin serum (Dr . CathyrnJohn, Children's Hospital, Boston, MA) was
used at a dilution of 1 :100 .
Membrane Proteins. CD2 was purified to homogeneity from Jurkat or SKW3 T
lymphoma lines by mAb affinity chromatography as previously described (19) . CD2 was
eluted from a TS2/18 CD2 mAb Sepharose column with 0.1 M Glycine HCI buffer, pH
2.75, containing 0.2 M NaCl and 0.2% Triton X-100 . The eluate was immediately
neutralized to pH 7 .4 with 0 .1 volume of 1 M Tris/HCI, pH 9.0, and used for further
studies after appropriate dilution . Protein was determined on ethanol-precipitated CD2
according to Lowry (24a) . LFA-1 was purified from the same SKW3 cell lysate using a
TS1/22 (2) mAb Sepharose column linked in series to the CD2 mAb Sepharose column
under identical chromatography and elution conditions .
'25I-CD2.
￿
Purified CD2 was labeled with ' 211 using 1,3,4,6-tetrachloro-3a,6a-diphen-
ylglycoluril (25) and extensively dialyzed against 10 mM Tris-HCI,-pH 8 .0, 0.14 M NaCl,
0.02% NaN 3 . The sp act was 3.8 X 10 8 cpm/nmol .
Immunofluorescent Flow Cytometry (26).
￿
Cells were stained with undiluted culture su-
pernatants containing mAbs, purified mAbs, or a subclass-matched irrelevant antibody
(Ab) . The second-step fluoresceinated sandwich reagent was goat F(ab')2 anti-mouse IgG
(H+L) (Cappel Laboratories, Cochranville, PA) . When flow microfluorometry was used
to analyze inhibition of anti-LFA-3 mAb binding by CD2, cells were preincubated with
CD2, LFA-1, or control buffers for 1 h at 4°C in 20 ul of HBSS with 15% BSA . All
samples receivingmembrane proteins, including the zero point oftitrations, were adjusted
to the same detergent and buffer concentrations . mAbs were added in an additional 20
dal and incubated another 30 min . mAb concentrations were the lowest, that gave optimal
'Abbreviations used in this paper :
￿
Ab, antibody ; CR1, complement receptor type 1 ; DAF, decay-
accelerating factor; LFA, lymphocyte function-associated antigen ; TUTS, TI I target structure.666
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Flow microfluorimetry analysis of LFA-3 expression . (A) Human E (gain = 1.0) ;
(B) sheep E (gain = 1 .0) ; (C) lymphoblastoid cell line B17B from a normal human donor (gain
= 0.25) .
staining (2 pg/ml for TS2/9 LFA-3 mAb), and comparable concentrations were used for
the nonbinding control IgGI . The cells were then washed and stained with the sandwich
reagent as above .
Rosetting assay.
￿
Cells were washed three times in RPMI 1640/10% FBS before use in
the rosetting assay . Sheep E or human E were mixed with lymphocytes at a ratio of 100
E per T cell in a total volume of 200 ul RPMI 1640/10% FBS. The cells were kept on ice
and centrifuged for 2 min at 200 g, and they were incubated on ice for 60 min . The tubes
were gently rocked to resuspend the pellet, and the rosettes were counted in a hemocy-
tometer (150-200 T cells were counted) .
Flow cytometry confirmed the predicted expression of LFA-3 on human E
(Fig . 1A) and revealed no crossreactivity of the LFA-3 mAb on sheep E (Fig.
1B). Calculation of fluorescence intensity (adjusted for differences in gain be-
tween samples)showed anti-LFA-3 bindingonhuman Eat a level of one-fourtieth
the level of binding on a lymphoblastoid cell line from a normal donor(Fig. 1 C) .
Peripheral blood human T lymphocytes rosetted with sheep E but not with
humanEas previously reported (9, 10) (Table I) . ThehumanJurkat T lymphoma
cell line (which expresses 1-2 x 105 molecules of CD2/cell [19]) was much more
efficient than PBL at rosetting with human E (Table 1) . CD2 mAb inhibited
autologous rosetting (Table I, Exp . 2), as previously described (13, 18) . Control
mAbs to the T lymphocyte surface proteins T4, T8, T3, and LFA-1 did not
inhibit human E rosetting (data not shown) . Strikingly, LFA-3 mAb completelyPLUNKETT ET AL .
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TABLE I
Effect ofmAb on Rosetting ofHuman TCells with Human or
SheepE
Cellswere pretreated with 5 wg/mlmAbfor30 minon ice, then washed
three times before addition to the rosetting assay .
* 5 pg/ml mAb was present throughout the rosetting assay .
inhibited rosetting of human T cells with human E (Table 1, Exp. 2) . Control
mabto glycophorin andCRI on human E had no effect .mAb to CD2 completely
inhibited Jurkat T cell rosetting with human and sheep E, while the mAb to
LFA-3 inhibited rosetting with human but not sheep E. The lack of effect of
anti-human LFA-3 mAb on rosetting with sheep E was expected from its lack of
reactivity with sheep E (Fig . 1) .
The cell type on which CD2 and LFA-3 were functionally important in E
rosetting was tested by pretreating only one cell type with the mAb (Table 1,
Exp . 3) . CD2 mAb was inhibitory only when T cells were pretreated, and LFA-3
mAb was inhibitory only when human E were pretreated .
These findings with a T cell tumor line were confirmed and extended with
human thymocytes and T lymphoblasts (Table 11) . In contrast to peripheral T
lymphocytes, thymocytes and PHA blasts rosetted efficiently with human E.
Rosetting of these cells with human E was inhibited at the level of the T cell with
CD2 mAb and at the level of the human E with LFA-3 mAb (Table II, Exps . 1
and 2) .
Removal of cell surface sialic acid with neuraminidase, and partial removal of
cell surface glycoproteins with proteases have previously been shown (18, 27) to
enhance a variety of cell-cell interactions, including E rosetting, possibly by
reducing charge-charge repulsion due to negative surface changes . Bromelain
andneuraminidase treatment ofPBL unmasked rosetting activity (Table 11, Exp .
Exp. Pretreatment
Rosettes
Human E Sheep E
1 PBL E
0 34
2* Jurkat E
Control Control 30 73
Anti-CD2 Anti-CD2 0 0
Anti-LFA-3 Anti-LFA-3 0 67
Anti-Glyco- Anti-Glyco- 32 63
phorin phorin 28 66
Anti-CRI Anti-CRI
3 Jurkat E
Control - 21 73
Anti-CD2 - 0 0
Anti-LFA-3 - 18 74
- Control 23 74
- Anti-CD2 23 75
- Anti-LFA-3 0 76668
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TABLE II
Effect ofmAb on Rosetting ofHumanTCells with HumanE
Pretreatment
￿
Percent Rosettes with Human E
Cells were pretreated with mAb as described in Table I .
3), and bromelain treatment of PHA-stimulated PBL increased the efficiency of
rosetting with human E (Table II, Exps . 2 and 3) . Pretreatment experiments
again showed that CD2 mAb inhibited at the level of the T lymphocyte and
LFA-3 mAb inhibited at the level of the human E. Bromelain or neuraminidase
treatment of human E rendered them agglutinatable by LFA-3 mAb (data not
shown) ; in no other case were cells agglutinated by LFA-3 mAb or CD2 mAb.
To determine if CD2 was functioning as a receptor for human E, we tested
whether the purified receptor could competitively inhibit the T lymphocyte-E
interaction . CD2 was solubilized with Triton X-100 from humanT lymphoblast
cell lines and purified by mAb affinity chromatography as described in Materials
and Methods . BSA was added to CD2 preparations to bind detergent (28) and
prevent damage to cells . Purified CD2 inhibited Jurkat T cell rosetting with
human E (Table III), and inhibited Jurkat T cell rosetting with sheep E as
previously described (19) .
Inhibition of autologous rosetting with purified CD2 suggested solubilized
CD2 could bind to E. Purified, 125I-labeled CD2 bound to human and sheep E
(3-10% of input counts in different experiments) . We tested whether pretreat-
ment ofhuman E with LFA-3 mAbwouldinhibitCD2 binding. '25I-labeledCD2
binding to human E was inhibited 99% by anti-LFA-3 (Table IV) . '25I-CD2
binding to sheep E was not inhibited by LFA-3 mAb, as expected from the lack
of reactivity of LFA-3 mAb with sheep E. Binding to either sheep or human E
was unaffected by control mAb to LFA-1, glycophorin, and CR1 . Inclusion of
CD2 mAb inhibited binding of ' 25I-CD2 to both cell types, showing that labeled
CD2 binding was specific .
Reciprocal experiments were carried out to determine whether CD2 could
competitively inhibit bindingofLFA-3mAb. E were preincubated with unlabeled
T cell E
Exp . I
Thymo-
cytes
Exp .
PHA-
PBL
2
Brome-
lain
PHA-
PBL
Exp .
Neura-
minidase
PBL
3
Brome-
lain
PBL
Control - 61 34 95 10 14
Anti-CD2 - 0 0 0 0 0
Anti-LFA-3 - 60 34 96 10 11
Anti-Glyco- - 59 ND ND ND ND
phorin - 59 ND ND ND ND
Anti-CR 1
- Control 60 31 91 8 ND
- Anti-CD2 61 26 92 8 ND
- Anti-LFA-3 0 0 2 0 ND
- Anti-Glyco- 60 ND ND ND ND
- phorin 58 ND ND ND ND
Anti-CR1PLUNKETT ET AL.
TABLE III
Inhibition by Purified CD2 ofHuman E and Sheep E Rosettes
Purified CD2 antigenin 30 A1 or a buffer control was mixed with 100 ,1
of 30% BSA.Jurkat cells in 70 jal were added to give afinal total volume
of 200pl with the indicatedfinalconcentration of CD2andwere incubated
for 30 min at 4°C before the E rosetteassay. Exp. 1: SKW3 CD2 in 0.2%
Triton X-100, 0.01 M Tris, pH 7.2, 0.15 M NaCl. Exp. 2: Jurkat CD2 in
0.1% Triton X-100, 0.01 M Tris, pH 7.2, 0.15 M NaCl. Controls had
identical detergent andbuffer concentrations.
TABLE IV
Inhibition of '25I-CD2Binding by Anti-LFA-3 Antibody
5 X 106 human or sheep E were incubated with 50 gl of mAb (either
hybridomaculture supernatant anti-CR1, anti-glycophorin, anti-CD2 and
anti-LFA-3, or 1:100 diluted ascites X63 and anti LFA-1) for 45 min at
4°C. Then 50 ul of .Y5í-CD2 (diluted to 4,000 cpm/,ul with 10% FBS/
RPMI 1640/2 mM Hepes, pH 7.4/3% BSA) wasaddedandthe incubation
was continued for another 2 h at 4°C. After incubation, the cells were
washed threetimes with 10% FBS/RPMI 1640/2 mM Hepes, pH 7.4 and
were counted in agamma counter.
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CD2 or control purified protein (LFA-1), then treated with the TS2/9 mAb to
LFA-3, washed, and stained with FITC-conjugated second antibody for analysis
by flow cytometry. Purified CD2 inhibited in a dose-dependent fashion the
binding of anti-LFA-3 to human E (Fig. 2). At 420 nM, CD2 reduced anti-LFA-
3 binding to human E by 79% (Fig. 2A). Half-maximal inhibition was attained
at ^-30 nM CD2 (Fig. 2C). The binding of a control antibody (anti-DAF) was
unaffected by CD2 (Fig. 2, B and C). As another control, preincubation with
purified LFA-1 (1,000 nM) had no affect on anti-LFA-3 binding to human E
(Fig. 2 C). These experiments strongly suggest that CD2 binds directly to LFA-3
on human E.
Functional studies showed that purified C132-mediated cell-cell adhesion (ag-
glutination) of both human and sheep E (Fig. 3, B and F). Similar results were
Exp. CD2
Jurkat cells
rosettingwith
human E
Jurkat cells
rosetting with
sheep E
Kg/ml
1 0 76 76
0.5 ND 32
5 12 4
2 0 65 80
5 16 13
Antibody
i2'I-CD2 Bound(cpm
Human E
±SD)
Specificity
Donor 1 Donor 2
SheepE
X63 3,697 ± 55 5,329 ± 79 10,392 t 143
Anti-LFA-1 3,898 t 40 5,547 t 56 11,168 ± 837
Anti-CRI 3,205 t 79 5,135 ± 97 11,375 ± 267
Anti-glycophorin 3,687 ± 20 5,524 ± 131 12,268 ± 32
Anti-LFA-3 42 t 24 57 t 26 10,660 ± 402
Anti-CD2 53 ± 14 34 ± 6 69 ± 6670
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Inhibition by CD2ofLFA-3 mAbbinding to humanE. (A) Flow microfluorimetry
histograms ofEstained with LFA-3 mAb (solid lines) or nonbinding IgGI control (dashed lines)
with or without 420 nM CD2 pretreatment . (B) Histograms of E stained with DAF mAb (solid
lines) or nonbinding IgG control (dashed lines) with or without 420 nM CD2pretreatment . (C)
Linear fluorescence intensity of E pretreated with CD2 and stained with DAF mAb (open
squares) and LFA-3 mAb (filled squares); untreated E (no detergent) stained with DAF mAb
(open triangle) and LFA-3 mAb (filled triangle) ; E pretreated with LFA-1 (1,000 nM) and
stained with DAFmAb(open circle) and LFA-3 mAb (filled circle) .
obtained with CD2 that was freed from detergent by sedimentation through a
sucrose gradient . Titration experiments showed that higher concentrations were
required to mediate adhesion (420 nM, data not shown) than to inhibit LFA-3
mAb binding . Although we do not know the physical form ofCD2 that mediates
cell-cell adhesion in this assay, we believe that CD2 either integrates into the E
membrane via a hydrophobic region or that it is present in a multimeric form,
perhaps as protein micelles . Heat-denatured CD2 did not agglutinate E (Fig .
3D), showing that adhesive activity is dependent on CD2 protein conformation .
Heat denaturation of CD2 also abrogates its ability to inhibit T cell-sheep E
rosetting (19) . Anti-LFA-3 mAb completely inhibited CD2-mediated human EPLUNKETT ET AL .
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FIGURE 3 .
￿
CD2 induced aggregation ofE. 107 E were mixed with 20 #g/ml CD2 with or
without 5,ug/ml mAb in the presence of 15% BSA. The mixture was centrifuged for 2 min
at 200gandincubated on ice for 2h. The cells were gently resuspended by rotating the tube
and photographed with a Nikon inverted microscope at an original magnification ofx 100
(x 77 shown here), except for anti-glycophorin induced aggregation of human E which was
photographed at x 40 (x 31 shown here) . (A) human E; (B)human E + CD2; (C) human E +
CD2+ LFA-3 mAb; (D) human E + CD2 denatured at 100°C for 15 min ; (E) sheep E; (F)
sheep E+ CD2; (G) sheep E+ CD2+ LFA-3 mAb; (H) human E + anti-human glycophorin
serum+ LFA-3mAb.672
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aggregation (Fig . 3 C), strongly suggesting that aggregation ofhuman E by CD2
is mediated by direct binding ofCD2 to LFA-3 . As expected, anti-LFA-3 had no
effect on aggregation of sheep E by CD2 (Fig . 3 G) . As a specificity control,
agglutination induced by a polyclonal serum to human glycophorin was unaf-
fected by anti-LFA-3 (Fig . 3H) .
Discussion
We have found that autologous rosetting of human T cells with E is due to
binding of CD2 on the T lymphocyte to LFA-3 on the erythrocyte, and have
used this system to explore the interactions between these molecules . Antibodies
to CD2 and LFA-3 inhibited rosetting by binding to the T lymphocyte and the
E, respectively . ThesemAbs inhibited rosetting by thymocytes, mitogen-activated
lymphocytes, and aT lymphoma tumor cell line . Peripheral blood T lymphocytes
do not rosette, but rosetting activity that was unmasked by neuraminidase or
bromelain treatment was CD2 and LFA-3 dependent . Detergent-solubilized,
purified CD2 bound to LFA-3 on E, as demonstrated by inhibition by LFA-3
mAb ofCD2 binding and reciprocal inhibition by CD2 of LFA-3 mAb binding.
Higher concentrations of purified CD2 (400 nM) aggregated E and this aggre-
gation was inhibited by LFA-3 mAb . These results show that CD2 binds to LFA-
3 on E, and that this interaction is sufficient to mediate cell-cell adhesion .
CD2 and LFA-3 previously have been shown to participate in a pathway of
antigen-independent adhesion ofT cells to B lymphoblastoid target cells (20),
and to be important in both T cytolytic and Th cell function (1-7) . In studies
analogous to those reported here (29), purified CD2 has been shown to bind to
LFA-3 on a B lymphoblastoid cell line . Antigen-specific cytolytic T lymphocyte-
mediated killing of this cell line has been shown to be inhibited by CD2 mAb
and LFA-3 mAb (2) . Thus, functionally important T cell-target cell interactions
and autologous rosetting involve similar interactions at the molecular level
between CD2 and LFA-3 . In further similarity to the human E rosetting system
studied here, CD2- and LFA-3-dependent (but not LFA-1-dependent) antigen-
independent conjugate formation can occur at 4°C (20) . The concentration at
which CD2 inhibited LFA-3 mAb binding suggests that the affinity of CD2 for
LFA-3 on E is -3 X 10'/M ; this is similar to its affinity for LFA-3 on B
lymphoblastoid cells of 1 .9 X 107/M (29) . Autologous rosetting is thus not an
aberrant crossreaction ; rather, it is an interesting model system for studying a
physiologically relevant molecular interaction .
A particularly interesting feature of autologous rosetting is its dependence on
T cell activation . Thymocytes and T cell blasts, but not peripheral blood
lymphocytes, form autologous rosettes, correlating with expression of activation
epitopes on the CD2 molecule (1, 30) . Whether CD2 from activated cells has a
higher affinity for LFA-3 than CD2 from resting peripheralT lymphocytes is an
interesting question for further work . Activation epitopes can be induced on
CD2 on resting T lymphocytes at 4 °C in 2 min (1, 30, 31), raising the possibility
that detergent solubilization could also change the conformation of CD2 and
alter its affinity for LFA-3 . We found that latent CD2- and LFA-3-dependent
rosetting by peripheral T lymphocytes could be unmasked by protease or
neuraminidase treatment . A reduction of net negative surface charge, lesseningPLUNKETT ET AL .
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charge repulsion between theT lymphocyte andE would be sufficient to explain
these effects, but it is possible that modification of CD2 is also important .
Neuraminidase treatment of T cells has been shown to unmask CD2 activation
epitopes (30) .
Although we found no rosetting of peripheral blood T lymphocytes with
human E, under less stringent conditions a small percentage of peripheral blood
T lymphocytes are found to form autologous rosettes (12-I4) . Removal of these
cells abrogates the autologous mixed lymphocyte reaction (12-14). The corre-
lation betweenautologous rosetting and activation suggests thesemay be a subset
of activatedT lymphocytes. We speculate that the CD2-LFA-3 interaction may
help mediate localization and extravasation of activated T lymphocytes at sites
of immune reaction . LFA-3 is expressed on endothelial cells (3, 32) . Lympho-
blasts extravasate throughout the circulation, in contrast to small lymphocytes,
which selectively recirculate through high endothelial venules (33) . This en-
hanced adhesion of activated T lymphocytes may explain why the majority of
activated T lymphocytes are not found in the circulation but are present in
lymph nodes or sites of antigenic stimulation .
Purification of T lymphocytes by sheep E rosetting has been known to cause
functional alterations . Larsson et al . (34) found that E rosetting primes T
lymphocytes to proliferate in response to lymphokines . Although this is an
artificial system, it suggests that interaction of CD2 with the LFA-3 ligand may
be a physiologically relevant pathway of T lymphocyte stimulation . Interaction
of CD2' thymocytes with LFA-3+ thymic epithelial cells via CD2/LFA-3 recep-
tor/ligand interactions appears of great importance in functional responses of
several different thymocyte subsets (21, 35).
Molecules similar to LFA-3 are present on E in other species. Human T
lymphocytes form CD2-dependent rosettes with E from human, sheep, dog,
horse, pig, and rabbit (8, 13, 17, 18, 36) . Autologous rosetting of thymocytes
has been demonstrated in the human, rabbit, rat, and pig (13, 16, 27, 37) . A 42
kD surface glycoprotein termed the T11 target structure (T 11TS) has been
defined on sheep E (38, 39). mAb to T11TS inhibit rosetting of sheep E with
either humanT cells or sheepT lymphocytes andinhibit a rangeofT lymphocyte
responses in sheep similar to those inhibited by LFA-3mAb in humans . Further-
more, the purified TIITS molecule competitively inhibits CD2 mAb binding .
Comparative studies suggest LFA-3 and T11 ITS are functional and structural
homologues, and the much higher density of T11 ITS on sheep E than LFA-3 on
human E may explain the much more avid rosetting of resting humanT cells
with sheep than human E (Hunig, T., M . Plunkett, M . Dustin, P. Selvaraj, and
T. Springer, unpublished observations) . While the significance of the expression
of LFA-3 on human E is still not fully appreciated, the conservation of expression
of similar structures on E in other mammals that can bind to human CD2 points
to its evolutionary importance .
Summary
CD2, also known as LFA-2, T11, and the E rosette receptor, is aT lymphocyte
surface protein functionally important in adhesion to target cells and T cell
triggering . LFA-3 is a widely distributed cell surface protein that functions in674
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adhesion on target cells. We find that LFA-3 is expressed on human E, and that
CD2 is a receptor for LFA-3 that mediates T cell adhesion to human E.
Pretreatment of T lymphocytes with CD2 mAb or of E with LFA-3 mAb inhibits
rosetting. Purified CD2 molecules bind to human E and inhibit rosetting. 12s1-
CD2 binding to E is inhibited by LFA-3 mAb; reciprocally, binding of LFA-3
mAb to human E is inhibited by pretreatment with purified CD2. Higher
concentrations of CD2 aggregate human E; aggregation is inhibited by mAb to
LFA-3.
Receivedfor publication 6 November 1986.
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